Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

News >

Unanswered Questions Remain in Frontline NSCLC

Kristi Rosa and Sara Karlovitch
Published: Tuesday, Jul 16, 2019

Lecia V. Sequist, MD, MPH,  the Landry Family Associate Professor of Medicine at Harvard Medical School, and director, Center for Innovation in Early Cancer Detection, Massachusetts General Hospital

Lecia V. Sequist, MD, MPH
The frontline treatment of patients with non–small cell lung cancer (NSCLC) has shifted in recent years, said Lecia V. Sequist, MD, MPH, and now the challenge lies in the decision of whether a patient should receive the combination of chemotherapy and immunotherapy or a checkpoint inhibitor alone.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication